Clinical trials
Lung Cancer Non-Small Cell Cancer (NSCLC) clinical trials
Below are recruiting lung cancer non-small cell cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 878 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Glendale, ArizonaAges 18 years+ - NCT06759857Enrolling by invitationPhase 3
New drug vs. afatinib for EGFR-mutant lung cancer
This trial compares a new drug (FHND9041) to a standard targeted therapy (afatinib) for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if the new drug works better or has fewer side effects.
BeijingAges 1.5 years+ - NCT06758401RecruitingPhase 3
Study of combination treatment for advanced lung cancer with high PD-L1
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
Fullerton, CaliforniaAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT06743581Recruiting
Cemiplimab and dupilumab before lung cancer surgery
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
Montreal, QuebecAges 18 years+ - NCT06745882RecruitingPhase 2
Pembrolizumab for Black Patients with Advanced Lung Cancer
This study tests if the drug pembrolizumab (Keytruda), alone or with chemotherapy, works well for Black patients with advanced non-small cell lung cancer (NSCLC) who haven't had treatment yet. The goal is to see real-world results in this group.
Tampa, FloridaAges 18 years+ - NCT06741085RecruitingPhase 2
Radiosurgery plus standard care for lung cancer spread to brain
This trial tests if adding stereotactic radiosurgery (focused radiation) to standard drug therapy is safe and effective for people with EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to improve control of brain metastases while continuing targeted therapy.
Miami, FloridaAges 18 years+ - NCT06417008RecruitingPhase 2/Phase 3
Combination targeted therapy for advanced EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06731907RecruitingPhase 2
Keytruda with or without chemo for advanced lung cancer
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
Lexington, KentuckyAges 18 years+ - NCT06730685Enrolling by invitation
Sarcopenia and cachexia in lung cancer patients
This study looks at muscle loss (sarcopenia) and weight loss (cachexia) in people with lung cancer. Researchers want to understand these conditions better to improve care.
Næstved, Region SjællandAges 18 years+ - NCT06731270RecruitingPhase 2
Diclofenac for advanced lung cancer on immunotherapy
This trial tests whether adding the anti-inflammatory drug diclofenac can help people with advanced non-small cell lung cancer whose tumors are growing while on a single immunotherapy drug. You must have been on immunotherapy for at least 12 weeks and have a growing tumor, but your doctor does not plan to change your treatment right away.
Atlanta, GeorgiaAges 18 years+ - NCT06738160RecruitingPhase 2
Combination therapy for advanced lung cancer with bone metastases
This trial tests a new combination of drugs and radiation to improve the effects of first-line chemotherapy and immunotherapy for patients with advanced non-small cell lung cancer that has spread to the bones. The goal is to help shrink tumors and potentially improve overall outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06731413RecruitingPhase 2
Mild chemo with immunotherapy for older adults with advanced lung cancer
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
Richmond, VirginiaAges 18 years+ - NCT06726720Recruiting
Real-world study of approved lung cancer drugs
This study looks at how well approved AstraZeneca drugs work for non-small cell lung cancer in everyday medical practice. It does not test new treatments, but gathers information to help doctors and patients make better decisions.
Aix-en-ProvenceAges 18 years+ - NCT06717295Recruiting
Blood test to find cancer early and track treatment
This study uses a blood test that looks at your platelets and immune cells to find common cancers early, and for certain cancers, to monitor how well treatment is working.
RosarioAges 40–75 - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Phoenix, ArizonaAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06699979Recruiting
Early lung cancer study with multiple tumors or cysts
This study looks at the genes and molecules of early-stage lung cancer in two groups: people with more than one lung tumor at the same time, and people whose lung cancer is tied to air-filled spaces (cysts) seen on a CT scan. The goal is to better understand these types of lung cancer.
Changsha, HunanAges 18 years+ - NCT06686771RecruitingPhase 3
Radiation for limited growth in advanced lung cancer on immunotherapy
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
Phoenix, ArizonaAges 18 years+ - NCT06687408Recruiting
Minimally invasive sleeve lobectomy for lung cancer
This study looks at a type of lung cancer surgery called sleeve lobectomy done with small incisions (minimally invasive). It aims to see if this approach is safe and effective for people with non-small cell lung cancer that requires removing a part of the lung and reconnecting the airway.
HangzhouAges 18 years+ - NCT06693336RecruitingPhase 2
Paclitaxel wafer during lung cancer surgery
This study tests a new way of giving paclitaxel—a chemotherapy drug—directly into the chest during lung cancer surgery. It aims to reduce the chance of cancer coming back after surgery, and may have fewer side effects than standard IV chemo.
Rochester, MinnesotaAges 18–80 - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Tucson, ArizonaAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+
Hear when a new Lung Cancer Non-Small Cell Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer non-small cell cancer (nsclc)?
- Yes. Clin2 currently lists 878 recruiting lung cancer non-small cell cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer non-small cell cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer non-small cell cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.